Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.955 SEK | -8.23% | -35.46% | -61.75% |
Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2023 | 35.2M 3.24M | Sales 2024 * | 105M 9.67M | Capitalization | 318M 29.28M |
---|---|---|---|---|---|
Net income 2023 | -249M -22.92M | Net income 2024 * | -244M -22.46M | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.16M | Net cash position 2024 * | 208M 19.12M | EV / Sales 2024 * | 1.05 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-2.11
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | -7.30% | ||
1 week | -34.25% | ||
Current month | -54.08% | ||
1 month | -41.31% | ||
3 months | -56.30% | ||
6 months | -58.92% | ||
Current year | -61.03% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 2.955 | -8.23% | 2 248 221 |
24-04-24 | 3.22 | +2.06% | 2,526,246 |
24-04-23 | 3.155 | -11.62% | 1,053,101 |
24-04-22 | 3.57 | -10.75% | 763,366 |
24-04-19 | 4 | -11.89% | 1,533,537 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 08:36 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.03% | 29.2M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.51% | 22.2B | |
-16.53% | 21.23B | |
-9.91% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ONCO Stock